Reducing Cancers Global Footprint and Impact
Harnessing resources beyond the US
At Pfizer the goal is to develop treatments that improve the lives of cancer patients around the world and ultimately reduces cancer's global impact. At Pfizer, we apply science and global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products.
Locations of Pfizer sites and academic partnerships
*The Centers for Therapeutic Innovation (CTI) is an entrepreneurial group within Pfizer that partners with leading academic medical centers and disease foundations with the aim of translating promising science in clinical candidates.
†Central European Cooperative Oncology Group (CECOG), Pfizer and Jonsson Cancer Center’s Revlon/UCLA Women’s Cancer Research Program, German Breast Group (GBG), Pfizer and the University of Texas MD Anderson Cancer Center, Spanish Breast Cancer Research Group (GEICAM)
Centers for Therapeutic Innovation (CTI)
Pfizer’s CTI is a unique model for academic-industry collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines.
A key aspect of CTI is its local centers in biomedical research hubs that enable Pfizer and academic teams to work side by side. This model represents a significant departure from the traditional lengthy and linear process of target discovery to eventual drug development.
Helping patients get access to our medicines worldwide
For more than 25 years, we have offered a number of assistance programs to help eligible patients access their prescription medicines. These programs have helped connect millions of uninsured and underinsured patients to the medications they need.
Our comprehensive assistance program, Pfizer RxPathways®, provides a range of support services, including insurance counseling, co-pay assistance, and access to medicines for free or at a savings.
We also support other organizations that focus on prescription access. In 2014 alone, we donated $6.3 million to US co-pay foundations for life-saving cancer medicines.